• Explore /
  • Poster
  • / A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC).

A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC).

Abstract Poster

Authors

null

Rebecca L. Porter

Dana Farber Cancer Institute, Boston, MA

Rebecca L. Porter , Jennifer Taylor Veneris , Nabihah Tayob , Gabriela West , Madeline Polak , Jeanette Gardner , Susana M. Campos , Carolyn N. Krasner , Elizabeth Katherine Lee , Joyce F. Liu , Elizabeth Stover , Alexi A. Wright , Ursula A. Matulonis , Panagiotis A. Konstantinopoulos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Clinical Trial Registration Number

NCT03835819

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS5611)

DOI

10.1200/JCO.2021.39.15_suppl.TPS5611

Abstract #

TPS5611

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Elizabeth Katherine Lee

First Author: Alexandra Leary

First Author: Alexandra Leary

First Author: Mario Javier Pineda